Evolution of the Quality of Life of Short Statured Children Treated With Growth Hormone : Evaluation at Adult Size (HF QoL)

Evolution of the Quality of Life of Short Stature Children Treated With Growth Hormone : Evaluation at Adult Size

Short stature can lead to emotional and social stress in children and adolescents, as well as their parents. Children and their parents want to be able to identify the cause of stunted growth and address it with treatment. Mitigating the impact of short stature on quality of life is one of the main goals of treatment. The quality of life in children can be measured using adapted self-questionnaires.

The investigative team published in 2019 the results of a preliminary study which shows that after one year of treatment with growth hormone, the quality of life improves in children, in particular on the scales emotional and social. These evaluations were carried out in particular thanks to the general questionnaire of quality of life: Pediatric Quality of Life Inventory (PedsQL) 4.0, but also via a specific questionnaire of the size: Quality of Life of Short Stature Youth questionnaire (QoLiSSY).

50 of the 74 patients who participated in this study have now reached their final height. The objective of the present study is to reassess this cohort using the QoLiSSY and PedsQL 4.0 questionnaires. The patient will be his own witness.

Study Overview

• Status: Completed
• Conditions: Growth Hormone Treatment
• Intervention / Treatment: Other: QoLiSSY and PedsQL 4.0 questionnaires

Detailed Description

Short stature can lead to emotional and social stress in children and adolescents, as well as their parents. Children and their parents want to be able to identify the cause of stunted growth and address it with treatment. Mitigating the impact of short stature on quality of life is one of the main goals of treatment. The quality of life in children can be measured using adapted self-questionnaires.

The investigative team published in 2019 the results of a preliminary study which shows that after one year of treatment with growth hormone, the quality of life improves in children, in particular on the scales emotional and social. These evaluations were carried out in particular thanks to the general questionnaire of quality of life: Pediatric Quality of Life Inventory (PedsQL) 4.0, but also via a specific questionnaire of the size: Quality of Life of Short Stature Youth questionnaire (QoLiSSY).

50 of the 74 patients who participated in this study have now reached their final height. The objective of the present study is to reassess this cohort using the QoLiSSY and PedsQL 4.0 questionnaires. The patient will be his own witness.

• Study Type: Observational
• Enrollment (Actual): 20

Contacts and Locations

Study Locations

• France
  • Paris, France, 75015
    • Hôpital Necker-Enfants Malades

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 15 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Adolescents and young adults followed or having been followed by the endocrinology, gynecology and pediatric diabetology department of the Necker Enfants Malades hospital, who reached their final height, who have been treated with growth hormone due to short stature and who had participed in the initial study : PedsQL 4.0 and QoLiSSY questionnaires completed at starting growth hormone therapy and after one year of growth hormone therapy.

Description

Inclusion Criteria:

• Adolescents and young adults followed or having been followed by the endocrinology, gynecology and pediatric diabetology department of the Necker Enfants Malades hospital and treated with growth hormone because of their short stature.
• Patient who participated in the initial study.
• Patient having reached the final height during the last consultation (growth rate less than 1 cm / year and / or bone age ≥ 15 years for girls, ≥ 17 years for boys).
• Holders of parental authority, minor patients and adult patients informed and not opposed to their participation in the study.

Exclusion Criteria:

- Refusal to participate in the study.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Growth hormone treatment; Adolescents and young adults followed or having been followed by the endocrinology, gynecology and pediatric diabetology department of the Necker Enfants Malades hospital, who reached their final height and who have been treated with growth hormone due to short stature.

Other: QoLiSSY and PedsQL 4.0 questionnaires; Patients have been reaching adult size complete the two questionnaires of the study : Quality of Life of Short Stature Youth questionnaire (QoLiSSY), assessing health-related quality of life in short stature youth. Pediatric Quality of Life Inventory (PedsQL) 4.0 : general health-related quality of life. The patients have previously completed the PedsQL 4.0 and QoLiSSY questionnaires when starting their growth hormone therapy and after one year of growth hormone therapy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evolution of the quality of life	Evolution of the quality of life in short patients who have been treated with growth hormone. Comparison of the scores of the initial Quality of Life in Short Stature Youth (QoLiSSY) questionnaire (start of growth hormone treatment) compared to the scores obtained when the patients reached their final height. QoLISSY questionnaires include two different forms: parent questionnaire (children aged 4 to 18 years of age) and child questionnaire (only for children ≥8 years of age). Both questionnaires have 50 items that cover three core domains (physical, emotional, and social), and additional complementary domains. The parent questionnaire includes two additional scales (16 items) assessing parental stress and anxiety. Scores are converted in SD scores and compared to age- and gender-specific data from a reference population of children and adolescents with short stature. A total score is computed as the mean score on the three core scales.	Day 0

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adult-size quality of life	Change in scores for the two questionnaires QoLISSY and Pediatric Quality of Life Inventory (PedsQL) 4.0 at adult size. Children younger than 8 years of age completed the questionnaire PedsQL 4.0 with their parents. The PedsQL has 23 items that investigate physical, emotional, and social QoL, as well as school functioning. This tool has been validated in the 2- to 18-year age range. The parents complete the questionnaire if the child is younger than 5 years. After that age, the child completes the age-appropriate version of the questionnaire (5-7, 8-12, or 13-18 years). The score is expressed as a percentage, with scores from 0 to 100%, 100% being the best score. Questionnaire subscales are considered evaluable if answers are provided for at least 80% of the items. High results being associated with a better quality of life related to health.	Day 0
Correlation between quality of life changes and clinical response to growth hormone therapy	Correlation between the changes in scores on the 2 questionnaires QoLISSY and PedsQL 4.0 at adult size and number of centimeters taken since the start of growth hormone treatment.	Day 0

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Investigators: Principal Investigator: Michel Polak, MD, PhD, Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Actual): March 8, 2022
• Primary Completion (Actual): March 7, 2023
• Study Completion (Actual): March 7, 2023

Study Registration Dates

• First Submitted: January 4, 2022
• First Submitted That Met QC Criteria: January 4, 2022
• First Posted (Actual): January 19, 2022

Study Record Updates

• Last Update Posted (Actual): November 15, 2023
• Last Update Submitted That Met QC Criteria: November 14, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: Growth hormone treatment; Quality of Life of Short Stature Youth (QoLiSSY) questionnaire; Pediatric Quality of Life Inventory (PedsQL) 4.0; Quality of life improvement
• Other Study ID Numbers: APHP211523; 2021-A02608-33 (Other Identifier: IDRCB number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No